GlassScriptPhysician profile
Michael A Gibson
NPI 1881920882
$7,790.43
in general payments reported to CMS, 2019-2025
19 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2021: $518 · 2022: $2,778 · 2023: $1,695 · 2024: $1,068 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382 · Travel and Lodging: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.70 |
| Travel and Lodging | $710.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,438.36 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Heartmate Touch |
| Abiomed | $1,850.49 | 2019-2025 | Impella |
| Regeneron Pharmaceuticals, INC. | $710.31 | 2023 | Libtayo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $441.92 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.30 | 2021-2024 | Jardiance |
| Cvrx, INC. | $182.51 | 2023-2024 | Barostim Neo System |
| Lemaitre Vascular, INC. | $114.34 | 2022 | |
| Novo Nordisk INC | $103.83 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $81.99 | 2022 | |
| Medtronic Vascular, INC. | $73.98 | 2019 | |
| United Therapeutics Corporation | $68.93 | 2024-2025 | Tyvaso, Tyvaso |
| Inari Medical, INC. | $60.51 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $55.67 | 2023-2024 | Verquvo, Winrevair |
| Impulse Dynamics (USA) INC. | $42.37 | 2023 | Optimizer |
| Daiichi Sankyo INC. | $40.00 | 2025 | Savaysa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $39.77 | 2023 | |
| Janssen Research & Development, LLC | $34.64 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.66 | 2023 | |
| Boston Scientific Corporation | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.